Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
Open Access
- 2 November 2026
- journal article
- other
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 10 references indexed in Scilit:
- Final analysis of the evaluation of safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment: An IMWG bone subcommittee studyBlood, 2025
- The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney DiseaseAnnals of Internal Medicine, 2025
- Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent PatientsJAMA, 2024
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupThe Lancet Oncology, 2023
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingBlood Cancer Journal, 2018
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2018
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 studyThe Lancet Oncology, 2018
- Denosumab for The Treatment of Bone Disease in Solid Tumors and Multiple MyelomaFuture Oncology, 2017
- An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myelomaAmerican Journal of Hematology, 2009
- Bisphosphonate nephrotoxicityKidney International, 2008